Safety of BNT162b2 mRNA COVID-19 vaccine in a cohort of elderly, immunocompromised patients with systemic vasculitis

Clin Exp Rheumatol. 2022 May;40(4):853. doi: 10.55563/clinexprheumatol/xj2pqk. Epub 2021 Sep 16.

Authors

Paolo Delvino¹, Emanuele Bozzalla-Cassione², Alessandro Biglia², Verdiana Serena Quadrelli², Alice Bartoletti², Carlomaurizio Montecucco², Sara Monti²

Affiliations

¹ Rheumatology Department, IRCCS Policlinico S. Matteo Foundation, University of Pavia, and PhD in Experimental Medicine, University of Pavia, Italy. paolo.delvino01@universitadipavia.it.
² Rheumatology Department, IRCCS Policlinico S. Matteo Foundation, University of Pavia, Italy.

PMID: 34528506
DOI: 10.55563/clinexprheumatol/xj2pqk

No abstract available

Publication types

Letter

MeSH terms

Aged
BNT162 Vaccine*
COVID-19* / prevention & control
Humans
Immunocompromised Host
RNA, Messenger
Systemic Vasculitis*

Substances

RNA, Messenger
BNT162 Vaccine